Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.

Steenbruggen TG, Steggink LC, Seynaeve CM, van der Hoeven JJM, Hooning MJ, Jager A, Konings IR, Kroep JR, Smit WM, Tjan-Heijnen VCG, van der Wall E, Bins AD, Linn SC, Schaapveld M, Jacobse JN, van Leeuwen FE, Schröder CP, van Tinteren H, de Vries EGE, Sonke GS, Gietema JA.

JAMA Oncol. 2020 Jan 30. doi: 10.1001/jamaoncol.2019.6276. [Epub ahead of print]

PMID:
31999296
2.

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.

Koole SN, van Driel WJ, Sonke GS.

Cancer. 2019 Dec 15;125 Suppl 24:4587-4593. doi: 10.1002/cncr.32505. Review.

PMID:
31967678
3.

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G.

N Engl J Med. 2020 Feb 6;382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11.

PMID:
31826360
4.

Heart failure after treatment for breast cancer.

Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS, Gietema JA, Hooning MJ, Seynaeve CM, Maas AHEM, Darby SC, Aleman BMP, Taylor CW, van Leeuwen FE.

Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1620. [Epub ahead of print]

PMID:
31721395
5.

Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.

Jacobse JN, Steggink LC, Sonke GS, Schaapveld M, Hummel YM, Steenbruggen TG, Lefrandt JD, Nuver J, Crijns APG, Aleman BMP, van der Meer P, Gietema JA, van Leeuwen FE.

Eur J Heart Fail. 2019 Nov 6. doi: 10.1002/ejhf.1610. [Epub ahead of print]

PMID:
31696625
6.

Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.

VAN Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, Ulrich CM, VAN Beurden M, Oldenburg HS, Sonke GS, VAN Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, VAN Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-DE Leeuw IM, Brug J, May AM, Buffart LM.

Med Sci Sports Exerc. 2020 Feb;52(2):303-314. doi: 10.1249/MSS.0000000000002154.

PMID:
31524827
7.

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.

de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M.

BMC Cancer. 2019 Sep 10;19(1):901. doi: 10.1186/s12885-019-6121-3.

8.

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Steenbruggen TG, Bouwer NI, Smorenburg CH, Rier HN, Jager A, Beelen K, Ten Tije AJ, de Jong PC, Drooger JC, Holterhues C, Kitzen JJEM, Levin M-, Sonke GS.

Breast Cancer Res Treat. 2019 Dec;178(3):597-605. doi: 10.1007/s10549-019-05427-1. Epub 2019 Sep 6.

PMID:
31493033
9.

Validation of the online prediction model CancerMath in the Dutch breast cancer population.

Hoveling LA, van Maaren MC, Hueting T, Strobbe LJA, Hendriks MP, Sonke GS, Siesling S.

Breast Cancer Res Treat. 2019 Dec;178(3):665-681. doi: 10.1007/s10549-019-05399-2. Epub 2019 Aug 30.

PMID:
31471837
10.

Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses.

Bernard P, Savard J, Steindorf K, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvao DA, Chinapaw MJ, Stuiver MM, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schmidt ME, Ulrich CM, Sonke GS, van Harten W, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Buffart LM.

J Psychosom Res. 2019 Sep;124:109746. doi: 10.1016/j.jpsychores.2019.109746. Epub 2019 Jun 23. Review.

PMID:
31443811
11.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2019 Nov 1;30(11):1842. doi: 10.1093/annonc/mdz215. No abstract available.

12.

Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.

Timmermans M, Zwakman N, Sonke GS, Van de Vijver KK, Duk MJ, van der Aa MA, Kruitwagen RF.

Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:364-369. doi: 10.1016/j.ejogrb.2019.07.010. Epub 2019 Jul 26.

PMID:
31400565
13.

Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer.

van Waart H, Buffart LM, Stuiver MM, van Harten WH, Sonke GS, Aaronson NK.

Support Care Cancer. 2019 Aug 8. doi: 10.1007/s00520-019-05019-1. [Epub ahead of print]

PMID:
31396745
14.

Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.

van der Hel OL, Timmermans M, van Altena AM, Kruitwagen RFPM, Slangen BFM, Sonke GS, van de Vijver KK, van der Aa MA.

Eur J Cancer. 2019 Sep;118:97-104. doi: 10.1016/j.ejca.2019.06.005. Epub 2019 Jul 18.

PMID:
31326731
15.

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.

Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AG, Verwaal VJ, Van de Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Retèl VP.

J Clin Oncol. 2019 Aug 10;37(23):2041-2050. doi: 10.1200/JCO.19.00594. Epub 2019 Jun 28.

PMID:
31251694
16.

Effect of physical exercise on cognitive function and brain measures after chemotherapy in patients with breast cancer (PAM study): protocol of a randomised controlled trial.

Witlox L, Schagen SB, de Ruiter MB, Geerlings MI, Peeters PHM, Koevoets EW, van der Wall E, Stuiver M, Sonke G, Velthuis MJ, Palen JAMV, Jobsen JJ, May AM, Monninkhof EM.

BMJ Open. 2019 Jun 20;9(6):e028117. doi: 10.1136/bmjopen-2018-028117.

17.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

PMID:
31209337
18.

[Cancer treatment; there are options].

Boersma LJ, Sonke GS, Verkooijen HM.

Ned Tijdschr Geneeskd. 2019 May 31;163. pii: D3768. Dutch.

PMID:
31187966
19.

Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.

Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK.

Eur J Surg Oncol. 2019 May 13. pii: S0748-7983(19)30444-5. doi: 10.1016/j.ejso.2019.05.006. [Epub ahead of print] Review.

PMID:
31128948
20.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
21.

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.

Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS.

Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10.

PMID:
31076546
22.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA.

Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.

PMID:
31046082
23.

Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.

Timmermans M, Sonke GS, Slangen BFM, Baalbergen A, Bekkers RLM, Fons G, Gerestein CG, Kruse AJ, Roes EM, Zusterzeel PLM, Van de Vijver KK, Kruitwagen RFPM, van der Aa MA.

Eur J Surg Oncol. 2019 Aug;45(8):1425-1431. doi: 10.1016/j.ejso.2019.04.009. Epub 2019 Apr 12.

PMID:
31027945
24.

MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients.

Engbersen MP, Van' T Sant I, Lok C, Lambregts DMJ, Sonke GS, Beets-Tan RGH, van Driel WJ, Lahaye MJ.

Eur J Radiol. 2019 May;114:146-151. doi: 10.1016/j.ejrad.2019.03.007. Epub 2019 Mar 15.

PMID:
31005166
25.

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.

van Baal JOAM, Van de Vijver KK, Algera MD, van der Aa MA, Sonke GS, van Driel WJ, Kenter GG, Amant FC, Lok CAR.

Gynecol Oncol. 2019 Jun;153(3):562-567. doi: 10.1016/j.ygyno.2019.03.257. Epub 2019 Apr 1.

PMID:
30948193
26.

Complex challenges for patients with protracted incurable cancer: an ethnographic study in a comprehensive cancer centre in the Netherlands.

Buiting HM, van Ark MAC, Dethmers O, Maats EPE, Stoker JA, Sonke GS.

BMJ Open. 2019 Mar 30;9(3):e024450. doi: 10.1136/bmjopen-2018-024450.

27.

The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.

Timmermans M, van der Hel O, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RF.

Gynecol Oncol. 2019 May;153(2):445-451. doi: 10.1016/j.ygyno.2019.02.019. Epub 2019 Feb 27.

PMID:
30826010
28.

The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.

Kramer I, Schaapveld M, Oldenburg HSA, Sonke GS, McCool D, van Leeuwen FE, Van de Vijver KK, Russell NS, Linn SC, Siesling S, Menke-van der Houven van Oordt CW, Schmidt MK.

J Natl Cancer Inst. 2019 Jan 30. doi: 10.1093/jnci/djz010. [Epub ahead of print]

PMID:
30698719
29.

Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer.

Timmermans M, Sonke GS, Van de Vijver KK, Ottevanger PB, Nijman HW, van der Aa MA, Kruitwagen RFPM.

Int J Gynecol Cancer. 2019 Jan 21. pii: ijgc-2018-000100. doi: 10.1136/ijgc-2018-000100. [Epub ahead of print]

PMID:
30665898
30.

Physical problems, functional limitations, and preferences for physical therapist-guided exercise programs among Dutch patients with metastatic breast cancer: a mixed methods study.

Ten Tusscher MR, Groen WG, Geleijn E, Sonke GS, Konings IR, Van der Vorst MJ, van Zweeden A, Aaronson NK, Stuiver MM.

Support Care Cancer. 2019 Aug;27(8):3061-3070. doi: 10.1007/s00520-018-4619-x. Epub 2019 Jan 4.

PMID:
30610432
31.

[Critical doctors and cognitive bias].

van der Wel MC, Sonke GS, Keijzers G.

Ned Tijdschr Geneeskd. 2018 Dec 5;162. pii: D3604. Dutch.

PMID:
30570926
32.

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.

van Ommen-Nijhof A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, van der Noort V, Jager A, Sonke GS; SONIA study steering committee.

BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.

33.

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6.

PMID:
30413379
34.

Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.

van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, Poortmans PMP, Siesling S.

Int J Cancer. 2019 Jan 15;144(2):263-272. doi: 10.1002/ijc.31914. Epub 2018 Nov 28.

35.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.

N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.

PMID:
30345884
36.

Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis.

Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, Galvão DA, Aaronson NK, Stuiver MM, Jacobsen PB, Verdonck-de Leeuw IM, Steindorf K, Irwin ML, Hayes S, Griffith KA, Lucia A, Herrero-Roman F, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, José Kersten M, Nollet F, Wenzel J, Wiskemann J, Brug J, Courneya KS.

J Natl Cancer Inst. 2018 Nov 1;110(11):1190-1200. doi: 10.1093/jnci/djy161.

37.

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM.

Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.

PMID:
30181323
38.

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM, Baaijens MHA, Sonke GS, Rutgers EJT, Russell NS, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Aug;119(4):408-418. doi: 10.1038/s41416-018-0159-x. Epub 2018 Aug 1.

39.

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.

Timmermans M, van der Aa MA, Lalisang RI, Witteveen PO, Van de Vijver KK, Kruitwagen RF, Sonke GS.

Gynecol Oncol. 2018 Sep;150(3):446-450. doi: 10.1016/j.ygyno.2018.07.004. Epub 2018 Jul 9.

PMID:
30001834
40.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G.

J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3.

PMID:
29860922
41.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155. Erratum in: Ann Oncol. 2019 Nov;30(11):1842.

42.

Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).

van der Noordaa MEM, van Duijnhoven FH, Loo CE, van Werkhoven E, van de Vijver KK, Wiersma T, Winter-Warnars HAO, Sonke GS, Vrancken Peeters MTFD.

Breast. 2018 Aug;40:76-81. doi: 10.1016/j.breast.2018.04.015. Epub 2018 May 22.

PMID:
29698928
43.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

van Driel WJ, Koole SN, Sonke GS.

N Engl J Med. 2018 Apr 5;378(14):1363-1364. doi: 10.1056/NEJMc1802033. No abstract available.

PMID:
29617590
44.

Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.

Timmermans M, Sonke GS, van Driel WJ, Lalisang RI, Ottevanger PB, de Kroon CD, Van de Vijver KK, van der Aa MA, Kruitwagen RF.

Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:98-102. doi: 10.1016/j.ejogrb.2018.02.029. Epub 2018 Mar 6.

PMID:
29525755
45.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

46.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS.

N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.

47.

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.

Dackus GMHE, Jóźwiak K, Sonke GS, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Linn SC.

Eur J Cancer. 2018 Feb;90:92-101. doi: 10.1016/j.ejca.2017.11.010. Epub 2017 Dec 21.

48.

Enrichment of high-grade tumors in breast cancer gene expression studies.

van Seijen M, Mooyaart AL, Mulder L, Hoogstraat M, Drukker CA, Loo CE, Pouw B, Sonke GS, Wesseling J, Lips EH.

Breast Cancer Res Treat. 2018 Apr;168(2):327-335. doi: 10.1007/s10549-017-4622-9. Epub 2017 Dec 18.

49.

No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.

Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM.

Eur J Cancer. 2018 Jan;88:31-37. doi: 10.1016/j.ejca.2017.10.030. Epub 2017 Nov 25.

PMID:
29179135
50.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.

O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.

Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21.

Supplemental Content

Support Center